Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

Abstract: Background: The long-acting injectable aripiprazole lauroxil (AL) initiated using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg dose of oral aripiprazole significantly improved symptoms of schizophrenia in a phase 3 study. The current analysis examined treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia initiating AL using ALNCD in a real-world setting. Methods: This retrospective analysis used administrative claims data from January 1, 2018, to December 31, 2022. Adult patients with schizophrenia and continuous plan enrollment ≥6 months before (baseline) and after (follow-up) AL initiation using ALNCD (index date) were eligible. Treatment patterns were evaluated during and after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared between the baseline and follow-up periods. Results: Included patients (Nf1152) had a mean age of 38.4 years; 36% were female. Most patients received AL 1064 mg (39%) or 882 mg (37%); 90.3% initiated treatment with ALNCD and their first AL injection on the same day, and 78% received a second AL dose. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all P